Vismodegib
- Generic Name
- Vismodegib
- Brand Names
- Erivedge
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14Cl2N2O3S
- CAS Number
- 879085-55-9
- Unique Ingredient Identifier
- 25X868M3DS
- Background
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis. In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.
- Indication
用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02371967
- Locations
- 🇸🇪
Skånes Universitetssjukhus; Hudkliniken, Lund, Sweden
🇸🇪SU/Sahlgrenska, Hudkliniken, Göteborg, Sweden
🇸🇪Norrlands universitetssjukhus; Onkologkliniken, Umeå, Sweden
A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- NYU College of Dentistry
- Target Recruit Count
- 2
- Registration Number
- NCT02366312
- Locations
- 🇺🇸
NYU Bluestone Center For Cllinical Research, New York, New York, United States
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT02337517
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02168530
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2018-07-20
- Target Recruit Count
- 9
- Registration Number
- NCT02115828
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- Conditions
- Bladder CancerNeoplasmsSolid TumorsBiliary CancerSalivary Cancer
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 673
- Registration Number
- NCT02091141
- Locations
- 🇺🇸
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Sarit Assouline
- Target Recruit Count
- 23
- Registration Number
- NCT02073838
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 9
- Registration Number
- NCT02067104
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Diffuse Large B-cell LymphomaIndolent Non-hodgkin LymphomaPrimary Central Nervous System LymphomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 31
- Registration Number
- NCT01944943
- Locations
- 🇫🇷
CHRU de Lille _ Hôpital Huriez, Lille, France
🇫🇷CHU de Nantes _ Hôtel Dieu, Nantes, France
🇫🇷Centre Henri Becquerel, Rouen, France
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01898598
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.